FIELD: medicine, oncology.
SUBSTANCE: method includes the consecutive stages: (a) administration of at least one dose of anti-angiogenic cyclo-(arginine-glycine-asparagine acid)-containing pentapeptide (pentapeptide cRGD), such as cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val); (b) administration of anti-tumor effective amount of radio immunotherapeutic agent(RIT) not later than in 1 hour following administration of pentapeptide cRGD at stage (a); and (c) administration of at least two additional doses of pentapeptide cRGD, where the first additional dose is administered within 2 days after RIT and each additional dose of pentapeptide cRGD is administered with intervals between doses not more than 2 days.
EFFECT: invention provides the synergic effect in regard to apoptosis of tumor cells and endothelial cells of tumor vessels.
30 cl, 6 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INHIBITING CEREBRAL TUMORS GROWTH DUE TO SELECTED ANTAGONISTS OF INTEGRINS | 2000 |
|
RU2255765C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| THERAPEUTIC COMPOUNDS AND METHODS | 2016 |
|
RU2770001C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
| INTERFERON PRODRUG FOR CANCER TREATMENT | 2018 |
|
RU2788736C2 |
| PHARMACEUTICAL COMPOSITION AND A METHOD OF TREATMENT OF PATIENTS WITH CEREBROSPINAL SCLEROSIS | 1992 |
|
RU2121850C1 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
